Replies to post #31583 on Anavex Life Sciences Corp (AVXL)

[imho]

I think it is very bullish if a significant majority showed improvement at 12 weeks versus a simple majority at 5 weeks. What we don't know right now is:

1. The amount of improvement in the MMSE score (how many points?);
2. What the dosages of A2-73 were and what number of the patients were on Aricept + A2-73? Since the dosage was not optimized at 5 weeks, was the significant improvement at 12 weeks as a result of dosage optimization, continued improvement at the same dosage across all patients, or both?

Very bullish if the data going forward confirms this in any significant way. Remains to be seen. But given that Aricept effect wears off after a few (6 months, I read somewhere), A2-73 improving over time would be astonishing.

IMHO